Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in <i>ATM</i> , <i>CHEK2</i> , or <i>PALB2</i>
Patients with <i>ATM</i>, <i>CHEK2</i>, or <i>PALB2</i> PVs had similar breast, colorectal, and pancreatic cancer mortality to the average genetically tested patient with their cancer type.
Authors
- Paul Abrahamse (ORCID: https://orcid.org/0000-0001-7433-153X)
- Steven J. Katz (ORCID: https://orcid.org/0000-0002-1151-861X)
- Timothy P. Hofer (ORCID: https://orcid.org/0000-0003-0434-8787)
- Kevin C. Ward (ORCID: https://orcid.org/0000-0001-5893-6192)
- Allison W. Kurian (ORCID: https://orcid.org/0000-0002-6175-9470)
- Christine M. Veenstra (ORCID: https://orcid.org/0000-0001-9947-7156)
- Scarlett Lin Gomez (ORCID: https://orcid.org/0000-0002-5143-4867)
- Ann S. Hamilton (ORCID: https://orcid.org/0000-0001-5898-2308)
- Lihua Liu (ORCID: https://orcid.org/0000-0003-2252-8407)
Institutions
- University of Southern California (US)
- Emory University (US)
- University of California, San Francisco (US)
- University of Michigan (US)
- VA Ann Arbor Healthcare System (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1200/jco-24-02442
- Citations
- 9
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 16.36